Systemic Sclerosis Market to Exhibit Growth at a 3% CAGR During the Forecast Period (2026–2036) as Emerging Therapies Expand Treatment Opportunities | DelveInsight
The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.


